Friday, February 16.
Some good news.
News of a good disposition seems more than a little sparse right now, so you really have to make the most of it, as and when.
There is some news, however, from Greece. And this news is pretty, pretty good. So we are going to break this particularly good news to you the only way we know how. Enjoy it y'all.
2K notes
·
View notes
all the news going around with unity's really got me worried for games that are already several years into development like Hollow Knight Silksong and Billie Bust up.
Just rough because I don't suppose a whole lot of games are going to be able to pivot game engines, let alone so late in development. Like it is easier said than done to pivot early in development but i've been following the development of several games that are years in at this point and the fact that they're grandfathering older titles into this is just... it's just bad.
The potential loss of games in terms of archival on such a massive scale....
560 notes
·
View notes
Ponder rolled his eyes. These things always sounded fine when he worked them out in his head. He'd read some of the old books, and sit and think for ages, and a little theory would put itself together in his head in a row of little shiny blocks, and then when he let it out it'd run straight into the Faculty and one of them, one of them, would always ask some bloody stupid question which he couldn't quite answer at the moment. How could you ever make any progress against minds like that? If some god somewhere had said, "Let there be light," they'd be the ones to say things like, "Why? The darkness has always been good enough for us."
Terry Pratchett, The Last Continent
160 notes
·
View notes
"Sanofi on Thursday said it’s planning to cut the U.S. price of its most popular insulin drug by 78% and cap monthly out-of-pocket costs at $35 for people who have private insurance starting next year.
In addition to its widely prescribed Lantus, the French drugmaker will reduce the list price of its short-acting insulin Apidra by 70%. Sanofi already offers a $35 monthly cap on insulin for uninsured diabetes patients.
The company is the last major insulin manufacturer to try to head off government efforts to cap monthly costs by announcing its own steep price cuts for the lifesaving hormone.
Eli Lilly and Novo Nordisk made similar sweeping cuts earlier this month after years of political pressure and public outrage over the high costs of diabetes care. The three companies control over 90% of the global insulin market.
... The change takes effect Jan. 1.
President Joe Biden’s Inflation Reduction Act capped monthly insulin costs for Medicare beneficiaries at $35, but it did not provide protection to diabetes patients who are covered by private insurance.
Sen. Bernie Sanders, a Vermont independent and the chairman of the Senate Health, Education, Labor and Pensions Committee, introduced a bill earlier this month that would cap the list price of insulin at $20 per vial.
Both the president and Sanders on Tuesday directly called on Sanofi to slash its prices after Novo Nordisk announced its own cuts that day.
Roughly 37 million people in the U.S., or 11.3% of the country’s population, have diabetes, according to the Centers for Disease Control and Prevention. Approximately 8.4 million [U.S.] diabetes patients rely on insulin, the American Diabetes Association said."
-via CNBC, 3/16/23
517 notes
·
View notes
mmgngm i was all excited tellin my mum abt me wanting to start bookbinding n she was just like well. what about your portfolio. are u sending it to people? youve been working on it for ages. yes i know!!!!!! im slow and disabled!!!! and want hobbies!!!!! bites you!!!!!!!!!!!
218 notes
·
View notes